ViiV Healthcare, July 2023 Join in the discussion with Dr Nneka Nwokolo on health issues faced by women living with HIV. Dr Nwokolo is Head of Global Patient Affairs at ViiV Healthcare and an honorary Consultant Physician in Sexual Health and HIV Medicine at Chelsea and Westminster Hospital in London where she continues to see patients in a combined general and menopause clinic. Date & time:...
Updated guidelines for PEP (Post-Exposure Prophylaxis) after non-occupational and occupational exposure to HIV
Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), June 2023 ASHM has updated the National Guidelines for Post-Exposure Prophylaxis (PEP) after non-occupational and occupational exposure to HIV . These guidelines outline the updated Australian recommendations for human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) following potential or known exposure...
Report: Adelaide Gay Community Periodic Survey, 2022
UNSW, June 2022 The report on the 2022 Adelaide Gay Community Periodic Survey has been published. The Gay Community Periodic Surveys (GCPS) are repeated, cross-sectional surveys of gay men conducted in the metropolitan areas of seven Australian states and territories. They are a key part of Australia’s behavioural surveillance system for HIV, monitoring sexual practices, drug use and patterns of...
Treatment as prevention works: HIV infections down by 66 per cent in NSW and Victoria
Kirby Institute, UNSW, 17th April 2023 A ten-year study into the impact of HIV ‘treatment as prevention’ has found that a 27 per cent increase in people accessing effective HIV treatment saw HIV infections decrease by 66 per cent between 2010 to 2019, in NSW and Victoria. The findings, published today in Lancet HIV, show the success of HIV treatment as prevention in reducing new HIV infections...
Agenda 2025: Ending HIV transmission in Australia in four years
Australian Federation of AIDS Organisations (AFAO), 17th June 2021 Agenda 2025 is a fully costed plan which draws upon evidence based research and is backed by top researchers, leaders, and clinicians in Australia’s community-led HIV response. Australia can end HIV transmission within four short years, averting over 6,000 infections by 2030 and saving $1.4 billion in health costs, according to a...
FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment
Poz.com, January 21, 2021 On January 21, the Food and Drug Administration (FDA) in the USA approved the first complete injectable HIV treatment regimen that does not require daily pills. Cabenuva, from ViiV Healthcare, is administered only once a month. It is approved for people with an undetectable viral load on their current therapy who wish to switch to a long-acting regimen. Cabenuva consists...